Date:1/26/2009

Reported Adjustments Adjusted -------- ----------- -------- Service revenue $538,892 $538,892 Reimbursement revenue 104,661 104,661 Total revenue 643,553 643,553 Costs and expenses: Direct costs 363,659 (15,000)(a) 348,659 Reimbursable out-of-pocket expenses 104,661 104,661 Selling, general and administrative 119,787 119,787 Depreciation 21,234 21,234 Amortization 4,509 4,509 Total costs and expenses 613,850 (15,000) 598,850 Income from operations 29,703 15,000 44,703 Other income (expense) 2,965 2,965 Income before income taxes 32,668 15,000 47,668 Provision for income taxes 12,840 7,080(a) 19,920 Effective tax rate 39.3% 41.8% Minority interest expense 1,001 1,001 Net income $18,827 $7,920 $26,747 Earnings per common share: ------------------- Basic $0.33 $0.46 Diluted $0.32 $0.46 Shares used in computing earnings per common share: ------------------- Basic 57,552 57,552 Diluted 58,171 58,171 Unaudited Six Months Ended ---------------- December 31, 2007
'/>"/>

SOURCE PAREXEL International Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related medicine news :

1. PAREXEL Announces Date of Second Quarter Fiscal Year 2009 Earnings Release and Conference Call
2. PAREXEL Reports Preliminary Second Quarter Results
3. PAREXEL International to Present at NASDAQ OMX 22nd Investor Program
4. PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results
5. PAREXEL International to Present at Robert W. Bairds 2008 Growth Stock Conference
6. PAREXEL International to Present at Bank of America 2008 Smid Cap Conference
7. Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share
8. Quest Diagnostics Reports Growth in Revenue and Earnings for Fourth Quarter 2008 and Provides 2009 Guidance
9. Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter
10. MedPredict Publishes Two New Reports Providing Expert Analysis of Malignant Hematology Drug Development
11. Thomson Reuters Publishes Three Pharma Matters Reports Covering the Third Quarter of 2008